18 February 2014 - Today, Biogen Idec Canada announces the Health Canada approval of Tecfidera (dimethyl fumarate) 240 mg strength capsule, a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (MS). Tecfidera was first approved by Health Canada in April 2013 as a 120 mg capsule indicated as monotherapy for the treatment of relapsing-remitting MS to reduce the frequency of clinical exacerbations and to delay the progression of disability.

For more details, go to: http://www.newswire.ca/en/story/1307275/health-canada-approves-new-strength-for-tecfidera-tm-a-first-line-oral-treatment-for-multiple-sclerosis